Is Mobiflex affected by genetics?

Yes — the active ingredient is metabolized by a gene known to vary between individuals.

Relevant genes: CYP2C9

Mobiflex is affected by pharmacogenetics through the CYP2C9 gene. Your genotype for this gene can change how your body processes Mobiflex, which can affect both how well it works and how well you tolerate it. The strongest evidence level on this page is Strong, based on CPIC or FDA guidelines.

What's in Mobiflex

tenoxicam affected by CYP2C9

Affected by CYP2C9 · CPIC · Strong evidence

Read the full tenoxicam genetics guide →

Tenoxicam phenotype recommendations

Published guidance from CPIC on how tenoxicam should be dosed or substituted based on your CYP2C9 phenotype.

Phenotype	What it means	Recommendation	Evidence
Normal Metabolizer CYP2C9	Your body processes the drug normally, so the usual starting dose works well.	CPIC Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.	Strong
Intermediate Metabolizer CYP2C9	Your body slows the drug slightly, but the usual starting dose is still fine.	CPIC Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals. CPIC Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo, or choose an NSAID metabolized by CYP2C9 but with a shorter half-life.	Moderate
Poor Metabolizer CYP2C9	Your body processes the drug very slowly, so it’s safer to switch to a different drug or one less affected by your genetics.	CPIC + CPIC Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo, or choose an NSAID metabolized by CYP2C9 but with a shorter half-life.	Moderate
Indeterminate CYP2C9	The impact of your genotype on response to this drug is unknown.	CPIC Initiate therapy with recommended starting dose.	—
Not available CYP2C9	The impact of your genotype on response to this drug is unknown.	CPIC Initiate therapy with recommended starting dose.	—

Source: CPIC

The gene behind the guidance

CYP2C9 Cytochrome P450 2C9

CYP2C9 metabolizes warfarin, phenytoin, celecoxib, and some NSAIDs. Variants that reduce its activity are most consequential for warfarin, where even small changes in drug clearance translate into very different doses (and a real bleeding risk if missed).

Poor metabolizers need substantially lower warfarin doses to hit the same INR target.

See all drugs affected by CYP2C9 →

Browse the full drug-class: Pain medications.

Related medications

Find out how your genetics affect Mobiflex

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Get your report Look up another medication

Informational only — not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.